Agoracom Blog Home

Posts Tagged ‘small cap’

« Older Entries
Newer Entries »

@goplantx $VEGA $PLTXF Prices Offering and Files Amended and Restated Preliminary Short Form Prospectus $VERY.ca $MEAT.ca $EATS.ca $VEGN.ca

Posted by AGORACOM-JC at 8:43 AM on Wednesday, February 17th, 2021
  • Filed an amended and restated short form preliminary short form prospectus in connection with the Offering.
  • The Offering will be at a price of $1.25 per unit of the Company for the issuance of a minimum of 8,000,000 Units to raise minimum total gross proceeds of $10,000,000 . 
  • The Offering, which will be conducted on a “best efforts” agency basis, is being led by Mackie Research Capital Corporation as lead agent and sole bookrunner.

VANCOUVER, BC , Feb. 17, 2021 – PlantX Life Inc. (the ” Company ” or ” PlantX “) (CSE: VEGA ) (Frankfurt: WNT1) (OTCQB: PLTXF) is pleased to announce that it has priced its previously announced offering (the ” Offering “) in its February 16, 2021 news release and has today filed an amended and restated short form preliminary short form prospectus in connection with the Offering. The Offering will be at a price of $1.25 per unit of the Company (a ” Unit “) for the issuance of a minimum of 8,000,000 Units to raise minimum total gross proceeds of $10,000,000 .  The Offering, which will be conducted on a “best efforts” agency basis, is being led by Mackie Research Capital Corporation (the ” Agent “) as lead agent and sole bookrunner.

Each Unit will consist of one (1) common share of the Company (an ” Unit Share “, each such common share in the authorized capital structure of the Company, a ” Common Share “) and one (1) Common Share purchase warrant (a ” Warrant “). Each Warrant will be exercisable at a price of $1.45 and will entitle the holder to purchase one additional Common Share (a ” Warrant Share “) for a period of two (2) years from the closing of the Offering (the ” Closing “), provided that , if, at any time, the daily volume weighted average trading price (or closing price on trading days when there are no trades) of the Common Shares on the Canadian Securities Exchange (the ” CSE “) or, if the Common Shares are not listed on the CSE, then on such other recognized Canadian stock exchange on which the Common Shares are then listed, equals or exceeds $2.50 per Common Share over any ten (10) consecutive trading days, the Company shall be entitled, at its option, within ten (10) business days following such ten-day period, to accelerate the exercise period of the Warrants through the issuance of a press release (the ” Acceleration Notice “) specifying the new expiry date and, in such case, the Warrants will expire on the 30th day following the issuance of the Acceleration Notice. From and after the new expiry date specified in such Acceleration Notice, no Warrants may be issued or exercised, and all unexercised Warrants shall be void and of no effect following the new expiry date.

The net proceeds raised under the Offering will be used to fund expansion, to continue to develop a user app, to evaluate and pursue potential strategic acquisitions, and for working capital and general corporate purposes.

The closing of the Offering is currently expected to be on or about March 11, 2021 or such other date as agreed upon between the Company and the Agent, and is subject to certain conditions including, but not limited to, the execution of an agency agreement and the receipt of all necessary regulatory approvals including the approval of the CSE.

The Units are to be sold on a “best efforts” basis through the Agent in the provinces of British Columbia , Alberta and Ontario , and such other jurisdictions as the Agent and the Company may agree other than Quebec , and in the United States pursuant to available exemptions from the registration requirements of the United States Securities Act of 1933, as amended (the ” U.S. Securities Act “) and all applicable U.S. state securities laws.

This press release does not constitute an offer to sell or a solicitation of an offer to buy any of these securities in the United States or to, or for the account or benefit of, U.S. persons. The securities described herein have not been and will not be registered under the U.S. Securities Act or any state securities laws and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available. “United States” and “U.S. person” are as defined in Regulation S under the U.S. Securities Act.

Read More: https://agoracom.com/ir/PlantX/forums/discussion/topics/755495-plantx-prices-offering-and-files-amended-and-restated-preliminary-short-form-prospectus/messages/2304002#message

Tags: , , , , , , , ,
Posted in Plant-Based Food, PlantX Life Inc. | Comments Off on @goplantx $VEGA $PLTXF Prices Offering and Files Amended and Restated Preliminary Short Form Prospectus $VERY.ca $MEAT.ca $EATS.ca $VEGN.ca

POET Technologies $PTK.ca $POETF Reports on Financing Activities Ahead of Friday’s Special Meeting

Posted by AGORACOM-JC at 8:34 AM on Wednesday, February 17th, 2021

Clarifies Position on Implementation of Potential Share Consolidation

  • Added approximately C$24 million (US$18.8 million) to the Company’s cash balance as a result of the successful closing of a brokered private placement, warrants and stock options exercised since October 1, 2020.

TORONTO, Feb. 17, 2021 — POET Technologies Inc. (” POET ” or the ” Company “) (TSX Venture: PTK; OTCQX: POETF), the designer and developer of the POET Optical Interposer™ and Photonic Integrated Circuits (PICs) for the data center and tele-communication markets, has added approximately C$24 million (US$18.8 million) to the Company’s cash balance as a result of the successful closing of a brokered private placement, warrants and stock options exercised since October 1, 2020.

Exercise of Options and Warrants
The Company revealed that it had received approximately C$10 million from the exercise of options and warrants since October 1, 2020. Approximately C$2.7 million (US$2.1 million) came from the exercise of approximately 7 million options by former employees and directors at prices ranging from C$0.28 to $0.52. Approximately C$7.3 million (US$5.7 million) in proceeds came from the exercise of warrants from its public offering in November 2016 in which 34.8 million units, consisting of one common share and one common share purchase warrant with an exercise price of C$0.52 per share were placed. The majority of those warrants remained unexercised until recently. From November 2, 2016 through September 30, 2020 only 2.8 million had been exercised. Since the beginning of Q4 2020, warrant holders have exercised approximately 14 million of the 32 million warrants outstanding, with approximately 18 million still unexercised. The Company believes that the outstanding warrants are held mainly by Canadian investors. If fully exercised, the remaining warrants would result in proceeds of approximately C$9.4 million (US$7.3 million) being realized by the Company. If unexercised, the warrants will expire on November 2, 2021.

Warrants Associated with Convertible Debentures
The Company also issued warrants in connection with its private placement of 2-year Convertible Debentures (the “Debentures”) in the period April through September 2019. Holders of the Debentures have the option of redeeming for cash or converting into units consisting of one common share and one common share purchase warrant. The common share purchase warrant forming a part of such unit has an exercise price of C$0.50 per share. Approximately C$5 million (US$3.75 million) worth of the Debentures were issued representing approximately 12.5 million warrants that would be issuable upon conversion into units. Since being issued, the Company’s debt has been reduced by C$750,000 resulting in the issuance of 1.875 million shares and an equal number of warrants. Assuming all of the remaining Debentures are converted and the associated warrants exercised, the remainder of the Company’s debt would be extinguished, and it would issue an additional 10.6 million units. Upon exercise of the associated warrants, the Company would receive an additional C$5.3 million (US$4.1 million).   Depending on the purchase date, holders of the Debentures have between approximately 2 and 7 months remaining from the date of this press release to convert or redeem the Convertible Debentures.

Special Meeting
The Company clarified its intention for the Special Meeting to be held on Friday, February 19, 2021, which is being held for the sole purpose of seeking authorization from the Company’s shareholders to amend the articles of the Company to enable the Board of Directors to consolidate the total outstanding shares within a certain range. The proposed range, to be effected if, as and when the Board of Directors determines within its sole discretion to do so, is on the basis of one post-Consolidation Common Share for a number of pre-Consolidation Common Shares of between two and 14. Thomas Mika, Executive Vice President and Chief Financial Officer, made the following statement: “The purpose of seeking authorization from the shareholders for a consolidation is both to enable an additional listing on the NASDAQ Capital Market and to offer a combination of share price and total shares outstanding that meets or exceeds the minimum requirements of some of the larger institutional investors in the United States and Canada. The Board of Directors intends to consolidate shares only in connection with the additional listing and to do so only when the timing is appropriate, both internally and when market conditions allow. We cannot predict when conditions may be appropriate so we cannot say for certain when a consolidation may be implemented. Until then, we intend to continue to be listed on the TSX Venture Exchange (the “TSXV”) in Canada and on the OTCQX in the United States. So far, we are pleased to say that we have received overwhelming support for the resolution that will be voted on Friday.”

The authority of the Board to consolidate the shares in its sole discretion is conditional upon the prior approval of the Company’s shareholders and the TSXV. If approved by the Company’s shareholders and the TSXV, the consolidation would take place upon a decision by the Company’s Board of Directors within the proposed range agreed to by the shareholders following approval.

The Company will hold its Special Meeting virtually at 1:00pm EST on February 19, 2021 via the LUMI Meeting platform. A Management Information Circular in respect of the meeting has been mailed to shareholders and is available under the profile of the Company on SEDAR. Only registered shareholders, or shareholders with control numbers will be able to attend. No presentation by company management will be conducted and questions will be limited solely to the formal business of the meeting.

The Company also reported that its Total Shares Outstanding increased in recent weeks to 332,338,897 as a result of the successful closing of a brokered private placement, warrants and stock options exercised since October 1, 2020 which added approximately C$24 million (US$18.8 million) to the Company’s cash balance.

Read More: https://agoracom.com/ir/POETTechnologies/forums/discussion/topics/755490-poet-technologies-reports-on-financing-activities-ahead-of-friday-s-special-meeting/messages/2303995#message

Tags: , , , , , , ,
Posted in POET Technologies | Comments Off on POET Technologies $PTK.ca $POETF Reports on Financing Activities Ahead of Friday’s Special Meeting

Valeo Pharma’s $VPH $VPHIF Hesperco Capsules at the Core of Montreal Heart Institute’s Hesperidin Coronavirus Clinical Trial $HLS.ca $MDP.ca $GUD.ca $RX.ca

Posted by AGORACOM-JC at 8:21 AM on Wednesday, February 17th, 2021
Valeo Pharma (@valeo_pharma) | Twitter
  • Montreal Heart Institute study to evaluate the ability of hesperidin, the medicinal ingredient in Hesperco™ capsules, to reduce the severity of symptoms and the need for hospitalization in COVID-19 patients
  • Hesperidin interferes / inhibits 2 key proteins of SARS-CoV-2 necessary for entry and infection of cells, suggesting that hesperidin may disrupt the replication rate of the virus and enable infected patients to build natural immunity
  • Hesperidin’s safety profile and immune-modulatory activity make it a highly promising molecule to intervene at various stages of the COVID-19 infection process
  • Hesperco TM capsules contain 500mg of high purity concentrated hesperidin

MONTREAL , Feb. 17, 2021 – Valeo Pharma Inc . ( CSE:VPH) (OTCQB:VPHIF) (FSE:VP2 ) (” Valeo ” or the ” Company “), a Canadian pharmaceutical company and its Hesperco™ development partner, Ingenew Pharma Inc. (“Ingenew”), are pleased to announce that Hesperco TM capsules, approved by Health Canada for immune support, will be at the core of the Montreal Heart Institute’s (“MHI”) clinical trial, “The Hesperidin Coronavirus Study”.

The MHI’s study will evaluate the effect of hesperidin on COVID-19 symptoms and its ability to reduce disease severity and the need for hospitalization in patients with COVID-19. The randomized, double-blind, placebo controlled study will enroll 216 confirmed COVID-19 symptomatic patients.

“The immune support properties of hesperidin, the medicinal ingredient contained in HESPERCO™ capsules, and its efficacy against other coronavirus strains are well documented in scientific literature. We are extremely proud to contribute in the fight against the COVID-19 virus with the prestigious MHI and our development partner Ingenew”, said Steve Saviuk , Valeo’s CEO. “Our involvement in this study aligns well with our vision to build a Canadian anchor pharmaceutical company and continued commitment to provide Canadian healthcare professionals and patients with innovative solutions to improve quality of life”.

Commenting on the  Montreal Heart Institute’s Hesperidin Coronovirus Study, Pierre Laurin , President and CEO of Ingenew, said: “We are pleased that MHI’s scientists  concur with our scientific findings.”

Read More: https://agoracom.com/ir/ValeoPharma/forums/discussion/topics/755488-valeo-pharma-s-hesperco-capsules-at-the-core-of-montreal-heart-institute-s-hesperidin-coronavirus-clinical-trial/messages/2303992#message

Tags: , , , , , , , , ,
Posted in Valeo Pharma Inc | Comments Off on Valeo Pharma’s $VPH $VPHIF Hesperco Capsules at the Core of Montreal Heart Institute’s Hesperidin Coronavirus Clinical Trial $HLS.ca $MDP.ca $GUD.ca $RX.ca

VIDEO – DraganFly $DFLY.ca $DFLYF and Windfall Geotek Landmines Solution Is a $700M Annual Market Whose Biggest Payoff Is Lives Saved $FLT.ca $UAVS $ALPP

Posted by AGORACOM-JC at 11:23 PM on Tuesday, February 16th, 2021

DraganFly ($DFLY) and Windfall Geotek ($WIN) have combined world-class drone technology with artificial intelligence to create an “incomparable solution” solving the global landmine epidemic.

With 60 – 110 million landmines needed to be found, the market is estimated to be worth $700M per year … But that pales in comparison to the value of lives that will be saved and economic prosperity created from ridding regions plagued by landmines.

Tags: , , , , , ,
Posted in AGORACOM Via Satellite, All Recent Posts, Draganfly Inc. | Comments Off on VIDEO – DraganFly $DFLY.ca $DFLYF and Windfall Geotek Landmines Solution Is a $700M Annual Market Whose Biggest Payoff Is Lives Saved $FLT.ca $UAVS $ALPP

VIDEO – Predictiv AI $PAI.ca $INOTF Is Already Commercializing Artificial Intelligence Driven Thermal Scanners With 62 Orders and 6 Channel Partners

Posted by AGORACOM-JC at 4:22 PM on Friday, February 12th, 2021

Our thesis at AGORACOM is that small cap disruptive technology companies are going to create 3X more wealth this decade than the last 3 decades combined, thanks to the convergence of powerful tech such as Artificial Intelligence, IoT sensors and so on.  

Why?  The costs to develop, deploy and scale new applications powered by these new technologies have come down to a point where small cap companies can compete head to head with just about anybody.  In fact, their size makes them more nimble and able to pivot into emerging trends much quicker than most tech giants.

Which companies will actually succeed in delivering is a determination you have to make.  But one company to consider is Predictiv AI (PAI:TSXV / INOTF:OTCQB), whose proprietary artificial intelligence and machine learning platform provides predictive and prescriptive solutions in the public safety sector.

In layman’s terms, PAI uses AI and Machine learning to create solutions that can predict danger.

For example, the Company’s Thermal Pass Fever Detection System was recently used at a Carolina Panthers NFL game.  Watch this short video to see it in action. Highlights of the system include:

  • 24 medical grade sensors
  • 1,200 readings per second
  • 1 person / second

As you can imagine, Thermal Pass can be used for almost any high-traffic location you can think of.  But the big question is …. will anybody actually use it?  Because truth be told 99% of us are not in a position to be able to assess how any AI solutions of any company stack up against the competition. The only thing we can rely on is AGORACOM’s favourite metric – 3rd party acceptance.  In short, if your product is good, people will want it.

By that measure, PAI is off to a great start with:

  • Orders for 62 units of ThermalPass since commercial launch in October.  Impressive.
  • Orders include hospitals, long-term care facilities, prisons and public schools.  More impressive
  • 6 channel partners.  This is really impressive because channel partners don’t waste their valuable time and resources with products they don’t think they can sell 

3rd party acceptance at this early stage – CHECK 

Watch our interview with Michael Lende in which we do a deep dive into PAI tech, products and future plans.

Tags: , , , , , ,
Posted in Predictiv AI | Comments Off on VIDEO – Predictiv AI $PAI.ca $INOTF Is Already Commercializing Artificial Intelligence Driven Thermal Scanners With 62 Orders and 6 Channel Partners

VIDEO – AGORACOM Beyond The Expert Welcomes Venture Capitalist Leigh Hughes To Discuss Mountain Valley MD $MVMD, Valeo Pharma $VPH $VPHIF and Xphyto Therapeutics $XPHY $XPHYF

Posted by AGORACOM-JC at 6:36 PM on Thursday, February 11th, 2021

AGORACOM followers have given us great feedback on our hit series “Beyond The Press Release” (BTPR) in which we speak with small cap CEO’s about important press releases in greater depth and, quite frankly, in layman’s terms for investors to truly understand their significance.  

Nowhere is this more important than in the world of disruptive technologies, biotech and pharma.  Each of these industries share two distinct traits:

  • The possibility for explosive growth with disruptive new products
  • Difficulty in conveying disruptive new products that, by their nature, have never been seen before by investors.

Whereas BTPR tells these stories from the side of small cap public companies, Beyond The Expert (BTE) tells these stories from the perspective of experts on these topics – and we couldn’t think of anyone better to start off this series than Leigh Hughes.  

Leigh is a Venture Capitalist who I’ve personally watched conduct incredible due diligence and invest into many small cap companies that have generated incredible returns over 12-18 month periods.    

Leigh is so good at what he does that many global private equity funds and institutions take his call and often follow him into investments he chooses to make.  Moreover, he serves as an advisor to several small cap companies.

If you ever wanted to truly learn how to become a great small cap investor, it doesn’t get much better than this.  

Without further adieu, watch this great interview with Leigh Hughes and make sure to provide us with your feedback via comments on Twitter, YouTube or wherever you may be watching or listening.

Tags: , , , , , , ,
Posted in AGORACOM Beyond The Expert, All Recent Posts, Featured, Mountain Valley MD, Valeo Pharma Inc, Xphyto Therapeutics | Comments Off on VIDEO – AGORACOM Beyond The Expert Welcomes Venture Capitalist Leigh Hughes To Discuss Mountain Valley MD $MVMD, Valeo Pharma $VPH $VPHIF and Xphyto Therapeutics $XPHY $XPHYF

POET Technologies $PTK.ca $POETF Completes C$15 Million Private Placement

Posted by AGORACOM-JC at 11:17 AM on Thursday, February 11th, 2021

  • Completed its previously announced brokered private placement (the “Placement”) of 14,706,000 units of the Company (the “Units”) at a price of $0.85 per Unit (the “Issue Price”) for gross proceeds of approximately $12.5 million.
  • Founder and former chairman of Origin House, Marc Lustig was the lead participant in the Placement.

TORONTO, Feb. 11, 2021 — POET Technologies Inc. (“POET” or the “Company”) (TSX Venture: PTK; OTCQX: POETF), the designer and developer of the POET Optical Interposer™ and Photonic Integrated Circuits (PICs) for the data center and tele-communication markets, announces that it has completed its previously announced brokered private placement (the “Placement”) of 14,706,000 units of the Company (the “Units”) at a price of $0.85 per Unit (the “Issue Price”) for gross proceeds of approximately $12.5 million. Founder and former chairman of Origin House, Marc Lustig was the lead participant in the Placement.

Cormark Securities Inc. acted as lead agent together with a syndicate of agents that included IBK Capital Corp. and PI Financial Corp. (collectively, the “Agents”). The Agents exercised in full an option (the “Agents’ Option”) for the purchase of an additional 2,941,200 Units on the same terms. Gross proceeds from the exercise of the Agents’ Option were approximately $2.5 million bringing the aggregate proceeds raised from the Placement to approximately $15.0 million from the issuance of the cumulative 17,647,200 Units.

Each Unit consists of one common share of the Company (a “Common Share”) and one Common Share purchase warrant (a “Warrant”). Each Warrant entitles the holder to purchase one additional Common Share at a price of $1.15 per Common Share for a period of 24 months from the issuance date thereof. The Warrants are subject to an accelerated expiry, exercisable at the option of the Company, if, on or following the date that is four months and one day after the date of issuance of the Units and prior to the expiry date of the Warrants, the daily volume weighted average trading price of the Common Shares exceeds $2.30 for ten consecutive trading days. The Issue Price represents a discount of 5.5% of the volume weighted average trading price of the Common Shares on the TSX Venture Exchange (“TSXV”) for the 5 trading days ended immediately prior to the announcement of the Placement on January 26, 2021.

Read more: https://agoracom.com/ir/POETTechnologies/forums/discussion/topics/755177-poet-technologies-completes-c-15-million-private-placement/messages/2303234#message

Tags: , , , , , , ,
Posted in POET Technologies | Comments Off on POET Technologies $PTK.ca $POETF Completes C$15 Million Private Placement

Draganfly $DFLY.ca $DFLYF and Windfall Geotek Advance Testing of Drone-Based #AI Solution for Landmine Detection $FLT.ca $UAVS $ALPP

Posted by AGORACOM-JC at 8:47 AM on Thursday, February 11th, 2021
  • Announced that it has advanced field testing of the EagleEye™ land mine detection solution with Windfall Geotek (TSX-V: WIN) (OTCQB: WINKF).
  • Windfall Geotek is a mining services company and a leader in the use of Artificial Intelligence (AI) and advanced knowledge-extraction techniques since 2005 in the mining sector.
  • This test included joint research, AI development, and engineering support for the development of drones and sensor equipment.

Los Angeles, CA., Feb. 11, 2021 — Draganfly Inc. (OTCQB: DFLYF) (CSE: DFLY) (FSE: 3U8) (“Draganfly” or the “Company”), an award-winning, industry-leading drone solutions and systems developer, today announced that it has advanced field testing of the EagleEye™ land mine detection solution with Windfall Geotek (TSX-V: WIN) (OTCQB: WINKF).

Windfall Geotek is a mining services company and a leader in the use of Artificial Intelligence (AI) and advanced knowledge-extraction techniques since 2005 in the mining sector. This test included joint research, AI development, and engineering support for the development of drones and sensor equipment.

Every day approximately 10 people around the world lose their lives or are maimed due to an anti-personnel mine (” APM “). This means that about 4,200 people are hurt or killed worldwide every year of which 35-42% are estimated to be children. It is estimated that there are between 60-110 million landmines in the ground right now and an equal amount is in stockpiles waiting to be planted or destroyed. Approximately 82 countries around the world are contaminated by APMs. Source: United Nations, Office for Disarmament Affairs .

An estimated US$540,000,000 was spent by industry and government in 2018 to deal with this problem of Landmines and Explosive Remnants of war (identify multiple APM and improvised explosive devices (IEDs) in a variety of terrain and contexts). Source: Landmine Monitor Report 2019 .

“Since 2020, Draganfly has invested in new capabilities in drone-based magnetometer technology and other remote sensing equipment,” commented Dinesh Kandanchatha, Chairman of Windfall Geotek. “The depth of the Draganfly engineering team, drone services group, and expert advisory in public safety was instrumental to get us to these first tests.”

“Windfall Geotek is the industry leader in AI-based digital exploration for mining. We now have the right mixture of equipment and data to move to the commercialization of an advanced AI-based platform to help solve the global problem of landmines,” said Cameron Chell, CEO of Draganfly. “The two companies share a mission of saving lives through technology. These tests are critical to helping create a new solution to this age-old problem. The new and expanded revenue streams for both companies in the Defense sector, Public Safety, and other markets are significant and represent an area where combined offering can excel.”

“For years our foundation has support organizations removing land mines, this type of technology and innovation by Draganfly and Windfall is exactly what is needed to solve this global challenge on a massive scale,” said Admiral Hayward, former head of the US Navy and member of the Joint Chiefs of Staff.

Watch the video to learn more.

Tags: , , , , , ,
Posted in Draganfly Inc. | Comments Off on Draganfly $DFLY.ca $DFLYF and Windfall Geotek Advance Testing of Drone-Based #AI Solution for Landmine Detection $FLT.ca $UAVS $ALPP

ImagineAR $IP.ca $IPNFF Announces Blue United Corporation as its Official Agency for Japan Expansion $DBO.ca $YDX.ca $SEV.ca $NTAR.ca

Posted by AGORACOM-JC at 8:00 AM on Wednesday, February 10th, 2021
http://www.smallcapepicenter.com/imagine%20ar%20squre.jpg
  • Announced a partnership with Blue United Corporation as its official agency to launch the ImagineAR Augmented Reality Platform in Japan
  • Blue United clients include Kashima Antlers, Matsumoto Yamaga , Yanmar, Under Armour, Omiya Ardija and the Pacific League Marketing (holding that represents the commercial interests of 6 teams of the Japanese Baseball League) and Sevilla FC, among others.

VANCOUVER, BC, Feb. 10, 2021 – ImagineAR (CSE: IP) (OTCQB: IPNFF) an Augmented Reality Company that enables sports teams, brands and businesses to instantly create mobile phone AR campaigns, is pleased to announce a partnership with Blue United Corporation as its official agency to launch the ImagineAR Augmented Reality Platform in Japan.  Blue United clients include Kashima Antlers, Matsumoto Yamaga , Yanmar, Under Armour, Omiya Ardija and the Pacific League Marketing (holding that represents the commercial interests of 6 teams of the Japanese Baseball League) and Sevilla FC, among others.

Blue United Corporation is a marketing, PR, and business development agency with offices in New York , Tokyo and Nagano . With a vast experience in International expansion and business development, Blue United Corporation, focuses on elevating brands on a global scale and help them on expanding internationally (business development and expansion, PR/Communications, social media, marketing, etc.), owns and manages the only football professional tournament between club teams that are part of the Pacific Rim Region (Pacific Rim Cup), and is the owner of esports Blue United eFC, current Asian champion of FIFA.

ImagineAR believes Blue United’s experience will significantly accelerate the Company’s presence and sales throughout Japan , a strategic new market for ImagineAR.

Takehiko Nakamura , CEO of Blue United, said; “ImagineAR is the most advanced sports fan engagement Augmented Reality platform in the global market today and we are excited to assist the company to launch its sales and marketing initiatives in Japan . Sports teams can drive new fan engagement and brand activation using ImagineAR and the Japan sports market requires this type of advanced immersive mobile experiential platform to drive new revenue streams.”

Read More: https://agoracom.com/ir/Imaginear/forums/discussion/topics/755071-imaginear-otcqb-ipnff-announces-blue-united-corporation-as-its-official-agency-for-japan-expansion/messages/2303014#message

Tags: , , , , , , ,
Posted in Imagine AR | Comments Off on ImagineAR $IP.ca $IPNFF Announces Blue United Corporation as its Official Agency for Japan Expansion $DBO.ca $YDX.ca $SEV.ca $NTAR.ca

Dr. Jamie Dwyer, Professor of Medicine at Vanderbilt University Joins Draganfly $DFLY.ca $DFLYF Board of Advisors $FLT.ca $UAVS $ALPP

Posted by AGORACOM-JC at 9:43 AM on Tuesday, February 9th, 2021
  • Subject to customary governance approvals, Jamie P. Dwyer M.D. has joined as a member of the Board of Advisors of Draganfly.
  • Dr. Dwyer is a professor of medicine at Vanderbilt University, President of the Collaborative Study Group, and Co-Founder of Innovative Renal Care. Previously he served on the faculty of Mayo Clinic.

Los Angeles, CA, Feb. 09, 2021 — Draganfly Inc. (OTCQB: DFLYF) (CSE: DFLY) (FSE: 3U8) (“Draganfly” or the “Company”), an award-winning, industry-leading drone solutions and systems developer, today announced, subject to customary governance approvals, Jamie P. Dwyer M.D. has joined as a member of the Board of Advisors of Draganfly.

Dr. Dwyer is a professor of medicine at Vanderbilt University, President of the Collaborative Study Group, and Co-Founder of Innovative Renal Care. Previously he served on the faculty of Mayo Clinic.

Dr. Dwyer has extensive experience working with FDA processes in particular devices and software.

Cameron Chell, CEO of Draganfly, said: “We are excited and truly honored to have Dr. Jamie Dwyer join Draganfly’s outstanding Board of Advisors. Dr. Dwyer brings an incredible understanding and experience with FDA processes and will be key in evolving our Vital Intelligence technology.”

“Draganfly has impressed me with the work they have done with their Smart Vital assessment platform and telehealth app. I am honored to assist a company that has built a solid foundation for innovation within the telehealth sector,” said Dr. Jamie Dwyer.

Dr. Dwyer holds an Sc.B degree in mathematics and Latin from Brown University, and an M.D. with Distinction from Brown University Medical School. He trained in Internal Medicine at Mayo Clinic Florida, where he served as Chief Medical Resident. He trained in Nephrology and Clinical Research at VUMC. After a faculty appointment at Mayo Clinic, he joined the Nephrology Division of VUMC in 2008.

Read More: https://agoracom.com/ir/Draganfly/forums/discussion/topics/754974-dr-jamie-dwyer-professor-of-medicine-at-vanderbilt-university-joins-draganfly-board-of-advisors/messages/2302818#message

Tags: , , , , , , ,
Posted in Draganfly Inc. | Comments Off on Dr. Jamie Dwyer, Professor of Medicine at Vanderbilt University Joins Draganfly $DFLY.ca $DFLYF Board of Advisors $FLT.ca $UAVS $ALPP

« Older Entries
Newer Entries »